Use of the integrated steady state rate equation to investigate product inhibition of human red cell adenosine deaminase and its relevance to immune dysfunction.
The analysis of progress curves using the integrated rate equation was applied to the adenosine deaminase-catalyzed conversion of adenosine to inosine. Adenosine deaminase was purified from human red blood cells of phenotypes ADA 1, ADA 2, and ADA 2-1. For all three types, no measurable product inhibition by inosine was observed. These results do not confirm the hypothesis that inosine accumulation in purine nucleoside phosphorylase deficiency causes adenosine deaminase inhibition, resulting in a common mechanism for the immune defects related to these two enzyme deficiencies.
D000243:Adenosine Deaminase / Q000097:blood* / Q000235:genetics; D058892:Adenosine Deaminase Inhibitors; D001327:Autoimmune Diseases / Q000201:enzymology*; D004912:Erythrocytes / Q000201:enzymology*; D006801:Humans; D007288:Inosine / Q000494:pharmacology; D007700:Kinetics; D009700:Nucleoside Deaminases / Q000097:blood*; D010641:Phenotype
D058892:Adenosine Deaminase Inhibitors; D007288:Inosine; D009700:Nucleoside Deaminases; D000243:Adenosine Deaminase